Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Johan M. van Rooijen"'
Autor:
Birgit S. Geurts, Thomas W. Battaglia, J. Maxime van Berge Henegouwen, Laurien J. Zeverijn, Gijs F. de Wit, Louisa R. Hoes, Hanneke van der Wijngaart, Vincent van der Noort, Paul Roepman, Wendy W. J. de Leng, Anne M. L. Jansen, Frans L. Opdam, Maja J. A. de Jonge, Geert A. Cirkel, Mariette Labots, Ann Hoeben, Emile D. Kerver, Adriaan D. Bins, Frans G.L. Erdkamp, Johan M. van Rooijen, Danny Houtsma, Mathijs P. Hendriks, Jan-Willem B. de Groot, Henk M. W. Verheul, Hans Gelderblom, Emile E. Voest
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-14 (2023)
Abstract Background In this study we aimed to evaluate the efficacy and safety of the PD-L1 inhibitor durvalumab across various mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) tumours in the Drug Rediscovery Protocol (DRUP
Externí odkaz:
https://doaj.org/article/0e6af27c660548eab8d0d86d81fe251d
Autor:
Ietsen de Groot, Ithamar Brinkman, Daphne Luijendijk-de Bruin, Sharon Poort, Johan M. van Rooijen
Publikováno v:
European Urology Open Science, Vol 33, Iss , Pp 48-55 (2021)
Background: Currently, metastatic hormone-sensitive prostate cancer (mHSPC) patients are often treated with docetaxel chemotherapy at the initiation of hormonal therapy. This treatment is based on the results of two pivotal trials. However, trial pop
Externí odkaz:
https://doaj.org/article/e2c4b0172aa44ff683b0b26a43942bc1
Autor:
Pauline A. J. Mendelaar, Marcel Smid, Job van Riet, Lindsay Angus, Mariette Labots, Neeltje Steeghs, Mathijs P. Hendriks, Geert A. Cirkel, Johan M. van Rooijen, Albert J. Ten Tije, Martijn P. Lolkema, Edwin Cuppen, Stefan Sleijfer, John W. M. Martens, Saskia M. Wilting
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
Molecular landscapes of metastatic colorectal cancers (mCRC) have often been restricted to coding regions or low numbers of patients. Here the authors present a whole-genome landscape of 429 mCRC patients, revealing the mutational impact of prior the
Externí odkaz:
https://doaj.org/article/33e7a2ece0a048d1b3f265617bf55c52
Autor:
Pauline A. J. Mendelaar, Marcel Smid, Job van Riet, Lindsay Angus, Mariette Labots, Neeltje Steeghs, Mathijs P. Hendriks, Geert A. Cirkel, Johan M. van Rooijen, Albert J. Ten Tije, Martijn P. Lolkema, Edwin Cuppen, Stefan Sleijfer, John W. M. Martens, Saskia M. Wilting
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-1 (2021)
Externí odkaz:
https://doaj.org/article/7b6240df8fa849e9a92909366528f2dd
Publikováno v:
Clinics and Practice, Vol 1, Iss 3, Pp e66-e66 (2011)
A 36-week-pregnant woman developed a symptomatic hydrocephalus. Chest imaging showed bihilar lymphadenopathy and histological examination of a mediastinal lymph node revealed non-caseating granulomas. After delivery, her neurologic complaints progres
Externí odkaz:
https://doaj.org/article/e1241462a80749408f3aa505342eaa52
Autor:
Ithamar Brinkman, Ietsen de Groot, Daphne Luijendijk-de Bruin, Johan M. van Rooijen, Sharon Poort
Publikováno v:
European Urology Open Science, Vol 33, Iss, Pp 48-55 (2021)
European Urology Open Science
European Urology Open Science
Background Currently, metastatic hormone-sensitive prostate cancer (mHSPC) patients are often treated with docetaxel chemotherapy at the initiation of hormonal therapy. This treatment is based on the results of two pivotal trials. However, trial popu
Autor:
Jolanda C. van Hoeve, Rob H.A. Verhoeven, Wouter B. Nagengast, Vera Oppedijk, Mitchell G. Lynch, Johan M. van Rooijen, Patrick Veldhuis, Sabine Siesling, Ewout A. Kouwenhoven
Publikováno v:
European journal of surgical oncology, 48(1), 106-112. Elsevier
European Journal of Surgical Oncology, 49(1), 106-112. W.B. Saunders Ltd
European Journal of Surgical Oncology, 49(1), 106-112. ELSEVIER SCI LTD
European journal of surgical oncology, 49(1), 106-112. W.B. Saunders Ltd
van Hoeve, J C, Verhoeven, R H A, Nagengast, W B, Oppedijk, V, Lynch, M G, van Rooijen, J M, Veldhuis, P, Siesling, S & Kouwenhoven, E A 2023, ' Managed Clinical Network for esophageal cancer enables reduction of variation between hospitals trends in treatment strategies, lead time, and 2-year survival ', European Journal of Surgical Oncology, vol. 49, no. 1, pp. 106-112 . https://doi.org/10.1016/j.ejso.2022.07.022
European Journal of Surgical Oncology, 49(1), 106-112. W.B. Saunders Ltd
European Journal of Surgical Oncology, 49(1), 106-112. ELSEVIER SCI LTD
European journal of surgical oncology, 49(1), 106-112. W.B. Saunders Ltd
van Hoeve, J C, Verhoeven, R H A, Nagengast, W B, Oppedijk, V, Lynch, M G, van Rooijen, J M, Veldhuis, P, Siesling, S & Kouwenhoven, E A 2023, ' Managed Clinical Network for esophageal cancer enables reduction of variation between hospitals trends in treatment strategies, lead time, and 2-year survival ', European Journal of Surgical Oncology, vol. 49, no. 1, pp. 106-112 . https://doi.org/10.1016/j.ejso.2022.07.022
Introduction: Despite evidence-based guidelines, variation in esophageal cancer care exists in daily practice. Many oncology networks deployed regional agreements to standardize the patient care pathway and reduce unwarranted clinical variation. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d357e2eed83f327ff14ab7dbd8fa6ad8
https://research.utwente.nl/en/publications/736c31c5-6e9d-4f18-9ad7-887b41449254
https://research.utwente.nl/en/publications/736c31c5-6e9d-4f18-9ad7-887b41449254
Autor:
Ithamar Brinkman, Jelmer J. van Zanden, Jan P. Kleinjan, Robbert Bakema, Johan M. van Rooijen
Publikováno v:
Anti-Cancer Drugs. 30:410-415
OBJECTIVE Certain polymorphisms of the DPYD gene encoding for the dihydropyrimidine dehydrogenase (DPD) enzyme are associated with fluoropyrimidine-induced toxicity. Dose reductions of the fluoropyrimidine prodrug capecitabine are recommended for pat
Autor:
Marcel Smid, Johan M van Rooijen, Edwin Cuppen, John W.M. Martens, Geert A. Cirkel, Stefan Sleijfer, Pauline A. J. Mendelaar, Job van Riet, Lindsay Angus, Mariette Labots, Saskia M Wilting, Mathijs P. Hendriks, Albert J. ten Tije, Martijn P. Lolkema, Neeltje Steeghs
Publikováno v:
Nature Communications, 12(1):574. Nature Publishing Group
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
Mendelaar, P A J, Smid, M, van Riet, J, Angus, L, Labots, M, Steeghs, N, Hendriks, M P, Cirkel, G A, van Rooijen, J M, Ten Tije, A J, Lolkema, M P, Cuppen, E, Sleijfer, S, Martens, J W M & Wilting, S M 2021, ' Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features ', Nature Communications, vol. 12, no. 1, 574, pp. 574 . https://doi.org/10.1038/s41467-020-20887-6
Nature Communications, 12(1):574. Nature Publishing Group UK
Nature Communications
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
Mendelaar, P A J, Smid, M, van Riet, J, Angus, L, Labots, M, Steeghs, N, Hendriks, M P, Cirkel, G A, van Rooijen, J M, Ten Tije, A J, Lolkema, M P, Cuppen, E, Sleijfer, S, Martens, J W M & Wilting, S M 2021, ' Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features ', Nature Communications, vol. 12, no. 1, 574, pp. 574 . https://doi.org/10.1038/s41467-020-20887-6
Nature Communications, 12(1):574. Nature Publishing Group UK
Nature Communications
In contrast to primary colorectal cancer (CRC) little is known about the genomic landscape of metastasized CRC. Here we present whole genome sequencing data of metastases of 429 CRC patients participating in the pan-cancer CPCT-02 study (NCT01855477)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69e19b969f07c930c611fe2bfafc00b1
https://pure.eur.nl/en/publications/1059c203-5843-47b5-9b13-81905f63a41e
https://pure.eur.nl/en/publications/1059c203-5843-47b5-9b13-81905f63a41e
Autor:
Bert van der Vegt, Carolien H.M. van Deurzen, Elisabeth G.E. de Vries, Carolien P. Schröder, Elise van Leeuwen-Stok, Hilde H. Nienhuis, Geertruida H. de Bock, Annemiek M E Walenkamp, Si-Qi Qiu, Johan M. van Rooijen, Hetty Timmer-Bosscha
Publikováno v:
Breast Cancer Research, Vol 22, Iss 1, Pp 1-10 (2020)
Breast cancer research, 22(1):30. BioMed Central Ltd.
Breast Cancer Research : BCR
Breast cancer research : BCR, 22. BioMed Central Ltd.
Breast cancer research, 22(1):30. BioMed Central Ltd.
Breast Cancer Research : BCR
Breast cancer research : BCR, 22. BioMed Central Ltd.
Background Breast cancer is rare in men, but management is focused on tumor characteristics commonly found in female breast cancer. The tumor microenvironment of male breast cancer is less well understood, and insight may improve male breast cancer m